Picroside II | CAS:39012-20-9 | Manufacturer ChemFaces

Picroside II

ChemFaces products have been cited in many studies from excellent and top scientific journals

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal

Citing Use of our Products

More Impact Factor than five Cite...

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $14.0 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Featured Products

More...

Resibufogenin

Catalog No: CFN98543
CAS No: 465-39-4
Price: $118/20mg

Myricitrin

Catalog No: CFN99840
CAS No: 17912-87-7
Price: $40/20mg

Lotusine

Catalog No: CFN93034
CAS No: 6871-67-6
Price: $218/10mg

6-Prenylnaringenin

Catalog No: CFN92017
CAS No: 68236-13-5
Price: $268/10 mg

Ganoderic acid F

Catalog No: CFN92055
CAS No: 98665-15-7
Price: $318/20mg

Acetyleugenol

Catalog No: CFN70222
CAS No: 93-28-7
Price: $30/20mg

Fisetin

Catalog No: CFN98176
CAS No: 528-48-3
Price: $30/20mg

Myricetin

Catalog No: CFN98877
CAS No: 529-44-2
Price: $40/20mg

(+)-Taxifolin

Catalog No: CFN99183
CAS No: 17654-26-1
Price: $70/20mg

Moscatin

Catalog No: CFN93148
CAS No: 108335-06-4
Price: $318/5mg

Description:

Picroside II has antioxidant, anti-inflammatory, immune regulatory, anti-virus and other pharmacological activities. It has potent anti-apoptotic activity against renal I/R injury by suppressing the TLR4/NF-κB signaling pathway, it can protect the ischemic kidney against renal fibrosis and improve the neurological function of rats upon cerebral ischemia reperfusion injury. Picroside II enhances nerve growth factor (NGF)-induced neurite outgrowth from PC12D cells by amplifying a down-stream step of MAP kinase in the NGF receptor-mediated intracellular MAP kinase-dependent signaling pathway.

Targets:

In vitro:

Acta Pharmacol Sin. 2005 Jun;26(6):729-36.

Inhibitory effect of picroside II on hepatocyte apoptosis.[Pubmed: 15916740 ]

To investigate the influence of Picroside II on hepatocyte apoptosis and its mechanism.
METHODS AND RESULTS:
Morphological changes and quantification of apoptotic cells were determined under transmission electron microscopy and flow cytometry respectively. DNA fragmentation was visualized by agarose gel electrophoresis. Semi-quantitative reverse transcription-PCR (RT-PCR) was used to analyze the expression of bcl-2 and bax genes. The content of manganese-superoxide dismutase (SOD) in liver mitochondria was detected by the Marland method. The content of malonic aldehyde (MDA) and the protein level in liver tissue were determined by thiobarbituric acid colorimetry and Lowry method. Picroside II decreased the levels of alanine aminotransferase and aspartate aminotransferase in the serum resulting from acute-liver injured mice induced with D-GalN and LPS; it also reduced the content of MDA, and thus, enhanced the activity of SOD. Picroside II 10 mg/kg was found to protect hepatocytes against apoptosis in a dose-dependent manner; it up-regulated the expression of bcl-2 genes, thus increased the bcl-2/bax ratio.
CONCLUSIONS:
Picroside II can protect hepatocytes against injury and prevent hepatocytes from apoptosis. It might by upregulating the bcl-2 gene expression and antioxidation.

In vivo:

Exp Ther Med. 2015 Apr;9(4):1253-1258.

Picroside II protects rat kidney against ischemia/reperfusion-induced oxidative stress and inflammation by the TLR4/NF-κB pathway.[Pubmed: 25780418]

Picroside II possesses a wide range of pharmacological effects and has been demonstrated to ameliorate cerebral ischemia and reperfusion (I/R) injury. However, its effects on renal I/R injury remain unclear. In the present study, the role of Picroside II in attenuating oxidative stress and the inflammatory response in a rat model of renal I/R injury was investigated.
METHODS AND RESULTS:
Sprague Dawley rats were subjected to 45 min of ischemia followed by 24 h of reperfusion. Prior to reperfusion, the rats were treated with Picroside II or an equal volume of phosphate-buffered saline. Renal function and histological changes were compared and the relevant parameters of oxidative stress and inflammation were detected. The expression of toll-like receptor 4 (TLR4) and nuclear factor κB (NF-κB; p65) were assessed by immunohistochemistry and western blotting. It was observed that renal function was significantly improved by treatment with Picroside II. Morphological analysis indicated that Picroside II clearly reduced tissue damage and the expression of TLR4 and NF-κB. Reverse transcription-quantitative polymerase chain reaction demonstrated that Picroside II inhibited the increase of tumor necrosis factor (TNF)-α, interleukin (IL)-1β and intercellular adhesion molecule (ICAM)-1 expression induced by I/R injury. Western blot analysis indicated that the expression levels of TLR4 and NF-κB were significantly downregulated in the Picroside II group compared with those in the I/R group.
CONCLUSIONS:
These results indicate that Picroside II treatment suppressed the TLR4/NF-κB signaling pathway, protecting renal tissue against I/R-induced oxidative stress and inflammatory response.

Int J Mol Sci. 2010 Nov 16;11(11):4580-90.

Neuroprotective properties of picroside II in a rat model of focal cerebral ischemia.[Pubmed: 21151457 ]

The aim of this study was to explore the effect of Picroside II on neuronal apoptosis and the expression of caspase-3 and poly ADP-ribose polymerase (PARP) following middle cerebral artery occlusion/reperfusion in male Wistar rats.
METHODS AND RESULTS:
Picroside II (10 mg/kg) was administered intravenously into the tail vein of the animals. The neurological function deficits were evaluated with the Bederson's test and the cerebral infarction volume was visualized with tetrazolium chloride (TTC) staining. The apoptotic cells were counted by in situ terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The immunohistochemistry stain and enzyme linked immunosorbent assay (ELISA) was used to determine the expressions of caspase-3 and PARP in brain tissue. The results indicated that rats in the control group showed neurological function deficit and cerebral infarction in ischemic hemisphere after two hours ischemia followed by 22 hours reperfusion. Caspase-3 and PARP expressions were also profound in the cortex, the striatum and the hippocampus, along with increased apoptotic cells in this group. Bederson's score, infarction volume, and expressions of caspase-3 and PARP, as well as apoptosis in the treatment group were,however, significantly decreased compared to those in the control group .
CONCLUSIONS:
Indicating that intravenous treatment with Picroside II might be beneficial to inhibit neuronal apoptosis and, thus, to improve the neurological function of rats upon cerebral ischemia reperfusion injury.

Modern Research in Inflammation, 2013, 02(3):46-53.

The anti-inflammatory effect of picroside II and the optimizing of therapeutic dose and time window in cerebral ischemic injury in rats[Reference: WebLink]

The aim is to optimize the anti-inflammatory effect and the therapeutic dose and time window of picrosede II by orthogonal test in cerebral ischemic injury in rats.
METHODS AND RESULTS:
The forebrain ischemia models were established by bilateral common carotid artery occlusion (BCCAO) methods in 30 Wistar rats. The successful models were randomly divided into sixteen groups according to orthogonal experimental design and treated by injecting Picroside II intraperitoneally at different ischemic time with different dose. The concentrations of aquaporins 4 (AQP4), matrix metalloproteinases9 (MMP9) and cyclooxygenase 2 (COX2) in serum and brain tissue were determined by enzyme linked immunosorbent assay to evaluate the therapeutic effect of Picroside II in cerebral ischemic injury. The best therapeutic time window and dose of Picroside II in cerebral ischemic injury were 1) ischemia 2.0 h with 20 mg/kg and 1.5 h with 20 mg/kg body weight according to the concentration of AQP4 in serum and brain tissue; 2) ischemia 1.5 h with 20 mg/kg and ischemia 2.0 h with 20 mg/kg according to the concentrations of MMP9 in serum and brain tissue; and 3) ischemia 1.5 h with 10 mg/kg and ischemia 1.5 h with 20 mg/kg according to the concentrations of COX2 in serum and brain tissue respectively. According to the principle of the lowest therapeutic dose with the longest time window, the optimized therapeutic dose and time window were injecting Picroside II intraperitoneally with 10 - 20 mg/kg body weight at ischemia 1.5 - 2.0 h in cerebral ischemic injury.

Kinase Assay:

Eur J Pharmacol. 2000 Oct 13;406(2):203-8.

Potentiation of nerve growth factor-action by picrosides I and II, natural iridoids, in PC12D cells.[Pubmed: 11020482]

Natural iridoid, picroside I (beta-D-glucopyranoside, 1a,1b,2,5a,6, 6a-hexahydro-6-hydroxy-1a-(hydroxymethyl)oxireno[4,5]cyclopenta[1, 2-c]pyran-2-yl, 6-(3-phenyl-2-propenoate)) o rPicroside II (beta-D-glucopyranoside, 1a,1b,2,5a,6, 6a-hexahydro-6-[(4-hydroxy-3-methoxybenzoyl)oxy]-1a-(hydroxymethyl )ox ireno[4,5]cyclopenta[1,2-c]pyran-2-yl) alone did not exhibit neuritogenic activity, but caused a concentration-dependent (>0.1 microM) enhancement of nerve growth factor (NGF, 2 ng/ml)-induced neurite outgrowth from PC12D cells.
METHODS AND RESULTS:
The picroside-induced enhancing action of NGF was abolished by GF109203X (2-[1-(3-dimethylaminopropyl)-indol-3-yl]-3-(indol-3-yl)maleimide) (0.1 microM), a protein kinase C inhibitor. Furthermore, PD98059 (2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one) (20 microM), a potent mitogen-activated protein (MAP) kinase kinase inhibitor, completely blocked the picroside-induced enhancement of neurite outgrowth in the presence of NGF (2 ng/ml), suggesting that picrosides activate the MAP kinase-dependent signaling pathway. Interestingly, no increase in the expression of phosphorylated MAP kinase was observed in picroside-treated (60 microM) PC12D cells in the presence of NGF (2 ng/ml).
CONCLUSIONS:
These results suggest that picroside I or Picroside II enhances NGF-induced neurite outgrowth from PC12D cells, probably by amplifying a down-stream step of MAP kinase in the NGF receptor-mediated intracellular MAP kinase-dependent signaling pathway.

Cell Research:

Clin Mol Hepatol. 2018 Mar;24(1):77-87.

Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis.[Pubmed: 29254285 ]

Cell lines:HepG2 cells
Concentrations: 0-300 μM
Incubation Time: 24 h
Method:
HepG2 cells are loaded with different concentrations of FFAs, picroside I, Picroside II, and silibinin for 24 hours. Cytotoxicity is measured via MTT assay.

Animal Research:

PLoS One. 2017 Apr 7;12(4):e0174414.

Picroside II protects the blood-brain barrier by inhibiting the oxidative signaling pathway in cerebral ischemia-reperfusion injury.[Pubmed: 28388666]

Animal Models: Adult male Wistar rats
Formulation: Normal saline
Dosages:20 mg/kg
Administration: i.p.

Product Name	Picroside II
Price:	$40 / 20mg
CAS No.:	39012-20-9
Catalog No.:	CFN99566
Molecular Formula:	C₂₃H₂₈O₁₃
Molecular Weight:	512.47 g/mol
Purity:	>=98%
Type of Compound:	Iridoids
Physical Desc.:	White powder
Source:	The roots of Picrorhiza scrophulariiflora
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Download:	COA MSDS SDF Manual
Similar structural:	Comparison (Web) (SDF)
Guestbook:

Source:	The roots of Picrorhiza scrophulariiflora
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	1.9513 mL	9.7567 mL	19.5133 mL	39.0267 mL	48.7833 mL
5 mM	0.3903 mL	1.9513 mL	3.9027 mL	7.8053 mL	9.7567 mL
10 mM	0.1951 mL	0.9757 mL	1.9513 mL	3.9027 mL	4.8783 mL
50 mM	0.039 mL	0.1951 mL	0.3903 mL	0.7805 mL	0.9757 mL
100 mM	0.0195 mL	0.0976 mL	0.1951 mL	0.3903 mL	0.4878 mL

CFN91711	6-O-Methylcatalpol	1617-84-1	376.4	C₁₆H₂₄O₁₀
CFN97148	Catalposide	6736-85-2	482.4	C₂₂H₂₆O₁₂
CFN98471	6'-O-p-Hydroxybenzoylcatalposide	355143-38-3	602.6	C₂₉H₃₀O₁₄
CFN99566	Picroside II	39012-20-9	512.47	C₂₃H₂₈O₁₃
CFN99451	Globularin	1399-49-1	492.5	C₂₄H₂₈O₁₁
CFN91677	10-O-trans-p-methoxycinnamoyl-catalpol	201605-27-8	522.5	C₂₅H₃₀O₁₂
CFN91676	10-O-[(E)-3,4-Dimethoxycinnamoyl]-catalpol	834155-36-1	552.5	C₂₆H₃₂O₁₃
CFN96021	Procumbide	20486-27-5	362.3	C₁₅H₂₂O₁₀
CFN98251	Catalpol	2415-24-9	362.3	C₁₅H₂₂O₁₀
CFN90761	Rehmannioside A	81720-05-0	524.5	C₂₁H₃₂O₁₅